CD22 and non-Hodgkin lymphoma: In the results of the cell communication analysis of RA and control mice in this study, it is not difficult to see that completely different from the control group, the CD45 signaling pathway in RA is exclusively contributed by Ptprc-Cd22, which in turn is a biomarker for a variety of malignant tumors such as leukemia and non-Hodgkin’s lymphoma, which may suggest that the CD45 signaling pathway is of great importance to be investigated in the transition from RA to leukemia.